REBACIN® prevents E6/E7-induced tumor growth
In the SCID model, REBACIN® treatment significantly
inhibited E6/E7-stimulated tumor growth after three injections (on Days
1, 14, and 28).13 Consistent with the finding that
REBACIN® inhibited HPV E6/E7 expression (Figure 1),
TC-1 cells with inhibition of E6/E7 expression after
REBACIN® treatment (as low as 19 μg/mL) were
significantly poor in inducing tumor growth (Figure 2C). Similarly,
after inhibition of E6/E7 expression, HeLa cells also show poor tumor
growth.13 These studies demonstrate that the serious
level of either TC-1 or HeLa cell-induced malignant transformation
depends on the expression level of E6/E7, suggesting a potential role of
REBACIN® in the prevention of E6/E7-stimulated
cervical carcinogenesis.